CymaBay Therapeutics, Inc.

LSE:0I5P Stock Report

Market Cap: US$3.7b

CymaBay Therapeutics Management

Management criteria checks 3/4

CymaBay Therapeutics' CEO is Sujal Shah, appointed in Mar 2017, has a tenure of 6.75 years. total yearly compensation is $2.56M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $13.21M. The average tenure of the management team and the board of directors is 3.5 years and 7 years respectively.

Key information

Sujal Shah

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage23.0%
CEO tenure7yrs
CEO ownership0.4%
Management average tenure3.5yrs
Board average tenure7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sujal Shah's remuneration changed compared to CymaBay Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$105m

Sep 30 2023n/an/a

-US$90m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$107m

Dec 31 2022US$3mUS$590k

-US$106m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$100m

Dec 31 2021US$2mUS$550k

-US$90m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$55m

Dec 31 2020US$3mUS$510k

-US$51m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$80m

Mar 31 2020n/an/a

-US$93m

Dec 31 2019US$3mUS$510k

-US$103m

Sep 30 2019n/an/a

-US$93m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$2mUS$452k

-US$73m

Sep 30 2018n/an/a

-US$58m

Jun 30 2018n/an/a

-US$48m

Mar 31 2018n/an/a

-US$39m

Dec 31 2017US$5mUS$393k

-US$28m

Compensation vs Market: Sujal's total compensation ($USD2.56M) is about average for companies of similar size in the UK market ($USD2.51M).

Compensation vs Earnings: Sujal's compensation has increased whilst the company is unprofitable.

CEO

Sujal Shah (50 yo)

7yrs

Tenure

US$2,561,783

Compensation

Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...

Leadership Team

NamePositionTenureCompensationOwnership
Sujal Shah
President7yrsUS$2.56m0.35%
$ 13.2m
Charles McWherter
President of Research & Development and Chief Scientific Officer11.2yrsUS$1.23m0.041%
$ 1.5m
Paul Quinlan
General Counsel3.4yrsUS$1.10m0.061%
$ 2.3m
Harish Shantharam
CFO, Principal Accounting & Financial Officerless than a yearno data0.018%
$ 653.7k
Ken Boehm
Senior Vice President of Human Resources3.7yrsno datano data
Patrick O'Mara
Senior Vice President of Business Development7.2yrsno datano data
Robert Martin
Senior Vice President of Manufacturing & Nonclinical Development8.9yrsno datano data
Klara Dickinson-Eason
Chief Regulatory & Quality Assurance Officer3.4yrsUS$1.24m0.018%
$ 682.0k
Becki Filice
Senior Vice President of Portfolio & Product Leadership3.3yrsno datano data
Ben Kozub
Head of Commercialless than a yearno datano data

3.5yrs

Average Tenure

60.5yo

Average Age

Experienced Management: 0I5P's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sujal Shah
President6.8yrsUS$2.56m0.35%
$ 13.2m
Thomas Wiggans
Independent Director2.9yrsUS$207.94k0%
$ 0
Jerrold Olefsky
Member of Clinical Advisory Board and Member of Scientific Advisory Boardno datano datano data
Caroline Loewy
Independent Director7.3yrsUS$215.44k0%
$ 0
Mayer Davidson
Member of Clinical Advisory Boardno datano datano data
Robert Sherwin
Member of Clinical Advisory Boardno datano datano data
Gerald Shulman
Member of Clinical Advisory Boardno datano datano data
Morris Birnbaum
Member of Scientific Advisory Boardno datano datano data
Steven Shoelson
Member of Scientific Advisory Boardno datano datano data
Robert Gelfand
Member of Clinical Advisory Boardno datano datano data
David Orloff
Member of Clinical Advisory Boardno datano datano data
Robert Wills
Independent Chairman9yrsUS$245.44k0.026%
$ 974.4k

7.0yrs

Average Tenure

69yo

Average Age

Experienced Board: 0I5P's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/22 13:43
End of Day Share Price 2024/03/22 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CymaBay Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG
John TannerCantor Fitzgerald & Co.